Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. It acquires, in-licenses, markets and distributes pharmaceutical products in Canada and internationally. Its products include nitrates portfolio, such as Elantan, Isoket and Deponit; Sintrom; Emselex/Enablex; Surgestone and Provames; Speciafoldine; Tredemine; Salagen; Estraderm MX, and Vancocin. It has presence in cardiovascular and women's health markets. It is focusing on prescription products in additional therapeutic areas, such as urology, central nervous system (CNS), oncology support, dermatology, ophthalmology, nephrology and anti-infectives. It owns, markets and distributes pharmaceutical products within various territories. The Company carries out business principally in Canada and Europe. It also sells products in Australia, South Korea and Mexico.